Glioblastoma is an aggressive primary malignant brain tumor characterized by diffuse invasion, rapid progression and resistance to conventional therapy. Although maximal safe resection followed by radiotherapy and temozolomide remains standard care for newly diagnosed disease, durable control is difficult and recurrence is almost inevitable. A major reason is the tumor’s metabolic plasticity. Many glioblastoma cells favor aerobic glycolysis, converting glucose-derived pyruvate into lactate even when oxygen is available, while poorly organized blood vessels create hypoxic regions that further stimulate glycolysis. This combination produces pronounced lactate accumulation and regional metabolic heterogeneity. Lactate can move among tumor regions and cell populations through monocarboxylate transporters, particularly MCT1 and MCT4, allowing metabolic cooperation between hypoxic, lactate-producing cells and better-oxygenated cells that may take it up as fuel.

Lactate’s effects are not confined to energy metabolism and extracellular acidification. Protein lactylation is the covalent addition of a lactyl group to lysine residues. In the canonical pathway, lactyl-CoA serves as the activated donor for this reaction, connecting cellular metabolism to chromatin regulation and protein function. Histone lactylation can alter transcriptional programs, whereas modification of non-histone proteins can influence protein stability, enzyme activity, DNA binding and signal transduction. The enzymes involved remain incompletely resolved. GTPSCS and ACSS2 have been implicated in generating lactyl-CoA, and p300 and KAT2A have been implicated as writers. A distinct, ATP-dependent route involving AARS1 and AARS2 can modify proteins without lactyl-CoA as an intermediate, although direct evidence for that route in glioblastoma is lacking. Sirtuins and histone deacetylases can remove lactyl groups, indicating that lactylation is reversible rather than permanent.

Glioblastoma does not simply generate more lactylation when glycolysis intensifies. Lactate abundance depends on the balance among production, uptake, export and use, while modification also depends on activated-donor availability, writer and eraser activity, and whether a particular lysine is accessible in the relevant protein. Accordingly, the review classifies the literature into tiers of mechanistic confidence. The strongest evidence involves a defined non-histone lactylation site validated through mass spectrometry, site-specific assays, competitive peptides, mutation or rescue. Histone mechanisms receive an intermediate classification when a specific site, enrichment at a regulatory region and functional perturbation are demonstrated. Effects linked only to lactate exposure, metabolic inhibition or global histone lactylation are considered suggestive. This distinction is important because reducing lactate can also change energy production, redox balance, acidity and signaling independent of lactylation.

Several histone pathways connect lactylation to glioblastoma growth. In preclinical glioma systems, hypoxia-associated HIF-1α signaling and H3K18 lactylation have been linked to increased YTHDF2 expression, BNIP3-dependent mitophagy and transcriptional programs that favor proliferation and hypoxic adaptation. Nuclear GTPSCS has been reported to generate lactyl-CoA and cooperate with p300, increasing H3K18 lactylation at the GDF15 promoter in models that also showed tumor growth and radioresistance. Separately, SUCLG2 knockdown reduced lactate and H4K16 lactylation, with the remaining H4K16 signal enriched at regulatory regions associated with proliferation and apoptosis. Another study linked H4K8 lactylation at the NUPR1 promoter to autophagosome–lysosome fusion and protective autophagy in glioblastoma cells, patient-derived material and in vivo models. These observations provide mechanistic support, but mutation of each histone residue was not used to prove causality in all cases.

Lactylation may also sustain glioma stem cells, the self-renewing malignant populations associated with recurrence. H3K18 lactylation has been reported to increase USP4 transcription, which stabilizes ANXA2 through deubiquitination and supports stem-cell phenotypes. Another study found that histone lactylation increased LINC01127 transcription, allowing this long noncoding RNA to regulate MAP4K4 in cis and activate JNK signaling associated with self-renewal. Non-histone modification can reinforce this metabolic state: lactylation of PTBP1 at lysine 436 stabilizes PFKFB4 messenger RNA, increases glycolytic flux and lactate production, and creates a positive-feedback loop between lactate accumulation and stem-cell maintenance. Site-specific non-histone evidence is particularly important here because the number of validated lactylated substrates in glioblastoma remains limited.

Treatment resistance is one of the clearest areas of convergence. Lactate-induced H3K9 lactylation at the MLH1 locus promotes an RNA-splicing event that reduces mismatch repair and is associated with temozolomide resistance. Reduced SIRT6 activity has also been linked to increased H3K9 lactylation at the MGMT promoter, greater MGMT expression and diminished temozolomide sensitivity. These associations involve both histone and non-histone substrates. In ALDH1A3-high glioma stem cells, lactylation of XRCC1 at lysine 247 increases its binding to importin-alpha and nuclear translocation, supporting single-strand-break repair after radiotherapy or temozolomide exposure. HAT1-catalyzed lactylation of RPA1 at lysine 88 enhances its binding to single-stranded DNA and homologous recombination, while a competitive peptide increased radiosensitivity in preclinical models. A separate pathway involving KU70 lactylation at lysine 317 enhances non-homologous end joining, reduces cytosolic DNA and limits cGAS–STING signaling. Blocking lactate transfer from tumor-associated macrophages to glioma stem cells or targeting KU70 lactylation improved responses to immune checkpoint blockade in immunocompetent intracranial models.

The microenvironment extends these effects beyond tumor cells. Lactate taken up by macrophages through MCT1 has been associated with H3K18 lactylation at the TNFSF9 promoter, M2-like polarization and glioma progression. Enhanced glucose metabolism has also been linked to immunosuppressive histone-lactylation programs in monocyte-derived macrophages. In glioma stem-cell and myeloid co-culture models, CBX3 was reported to bias p300 toward lactyl-CoA-dependent histone lactylation, increasing transcription of CD47 and limiting phagocytosis by microglia and macrophages. Another route links lactate to H3K18 lactylation at the ARNTL promoter and BMAL1 lactylation at lysine 123, increasing VEGFA expression and reducing bevacizumab sensitivity in cell, xenograft, animal and clinical-cohort analyses. These results implicate lactate exchange and lactylation in immune suppression, but lactate can also influence immune cells through acidity, receptor signaling and metabolic substrates independently of protein modification.

Therapeutic experiments have therefore targeted several points along the pathway. In glioblastoma models, inhibiting lactate dehydrogenase with stiripentol reduced lactate production and tumor growth, while MCT1 inhibition decreased glioma stem-cell viability and proliferation. Neither is specific to lactylation. Other preclinical strategies reduce lactate or alter its regulatory machinery, including PPARα activation, SIRT6 activation, GTPSCS knockdown and inhibition of a TREM1-dependent pathway. One site-directed approach used a competitive peptide against RPA1 lysine 88 lactylation and increased radiosensitivity in preclinical models. Separately, oxamate, an upstream intervention that reduces lactate production, enhanced CAR-T-cell activity in glioma xenografts while reducing H3K18 lactylation and immune-suppressive metabolic programs. These findings suggest possible combinations with radiotherapy, chemotherapy, anti-angiogenic therapy or immunotherapy, but they do not establish clinical efficacy. Major barriers include delivery across the blood–brain and blood–tumor barriers, possible effects on normal brain metabolism, incomplete understanding of lactylation writers, readers and erasers, and a lack of standardized site-specific measurements.

Translation also requires better biological and methodological resolution. Glioblastoma contains plastic malignant-cell states and distinct metabolic niches, so lactylation probably varies with oxygen availability, cell state and neighboring cell types. Spatial transcriptomics generally reveals expression associated with lactate metabolism rather than protein lactylation itself; direct spatial mapping will require modification-specific antibodies, spatial proteomics or site-resolved mass spectrometry. Existing patient-stratification models largely analyze lactylation-related gene expression in public transcriptomic datasets and have not demonstrated that they predict treatment response in actual clinical cohorts. Normal brain physiology also includes lactate metabolism and lactylation, raising safety questions if lactate production or the modification is broadly inhibited. The review’s central conclusion is therefore one of promise and restraint: lactylation is a credible mechanism connecting glioblastoma metabolism with progression and resistance, but clinically useful targeting will require site-specific interventions, patient-derived and immunocompetent models, direct biomarker measurement, standardized assays and prospective validation in patients.

Subject of Research: Protein lactylation in glioblastoma metabolism, malignant progression and treatment resistance

Article Title: Lactylation in glioblastoma: mechanisms and therapeutic perspectives

Article References: Huang, L., Huang, B., Kuang, S., & Yan, Y. (2026). Lactylation in glioblastoma: mechanisms and therapeutic perspectives. Frontiers in Cell and Developmental Biology, 14, Article 1940871. https://doi.org/10.3389/fcell.2026.1940871

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1940871

Keywords: glioblastoma, lactylation, lactate metabolism, cancer metabolism, epigenetics, glioma stem cells, treatment resistance, tumor immunity, DNA repair, brain tumor, mechanisms, therapeutic

The researchers built an unsupervised framework that combines a deep autoencoder, a neural network trained to compress and then reconstruct its own input, with K-Means clustering, a classical algorithm that partitions data points by their distance to group centroids. The autoencoder first learns to squeeze each 224-by-224-pixel MRI image through a bottleneck of dense layers with 128 and then 64 ReLU-activated neurons, forcing the network to distill the scan into a compact latent vector. A mirrored decoder then attempts to rebuild the original image from that compressed code. By minimizing the reconstruction error between the original scan and its reconstruction, the network is pushed to preserve only the features that matter most: structural variations, intensity distributions, and texture-related abnormalities associated with tumor progression.

Once the autoencoder has been trained, the researchers discard the decoder and keep the encoder as a feature extractor. Every tumor image in their dataset, drawn from a publicly available Kaggle collection of 1,500 brain tumor scans, is passed through the encoder to produce a latent embedding. These embeddings, rather than the raw pixel values, are then fed into K-Means clustering with k-means++ centroid initialization, twenty initialization runs, and a fixed random seed for reproducibility. The result is a partition of the scans into three latent imaging-pattern groups, labeled Group 1, Group 2, and Group 3 purely for visualization purposes.

The authors are careful to stress that these three groups are not clinically validated tumor grades. Because the underlying dataset provides only tumor-versus-non-tumor labels rather than expert pathological grading, the clusters represent statistical similarities in imaging characteristics discovered by the algorithm, not medical severity categories. This distinction matters: the framework is positioned as an exploratory computational tool for pattern analysis, one that could support future research in settings where labeled data are limited, rather than as a diagnostic system ready for the clinic.

To judge whether the clustering was actually meaningful, the team benchmarked their approach against two popular hybrid alternatives: PCA plus K-Means, which uses classical linear dimensionality reduction, and VGG16 plus K-Means, which extracts features from a pre-trained convolutional neural network. Three standard internal validation metrics were computed for each method. The Silhouette Score measures how similar each point is to its own cluster compared with neighboring clusters, with higher values indicating better separation and compactness. The Calinski-Harabasz Index captures the ratio of between-cluster dispersion to within-cluster dispersion, again favoring higher values. The Davies-Bouldin Index, by contrast, rewards lower scores, since it quantifies average similarity between clusters based on inter- and intra-cluster distances.

The autoencoder-based method won on every metric. It achieved a Silhouette Score of 0.1601, a Calinski-Harabasz Index of 444.42, and a Davies-Bouldin Index of 1.939, the best results among all evaluated configurations. The VGG16- and PCA-based pipelines produced higher intra-cluster variance and weaker separation. The authors interpret these numbers as evidence that the deep learned features capture non-linear imaging characteristics that both linear PCA and transfer-learned CNN features miss. They also acknowledge that a Silhouette Score of roughly 0.16 indicates moderate separability, meaning some overlap persists between the discovered groups, a limitation they discuss openly.

Qualitative evidence came from t-distributed Stochastic Neighbor Embedding, or t-SNE, a technique that projects high-dimensional latent vectors into two dimensions for visualization. In the resulting plot, each point represents one MRI scan, colored by its assigned cluster. The three clusters appear as visibly distinct spatial groupings, supporting the idea that the autoencoder’s latent space organizes scans by imaging-pattern similarity. A bar chart of the cluster distributions further showed that the autoencoder-based method produced a more balanced spread of images across the three groups than either competing method, capturing more of the scans that the authors describe as representing more severe imaging patterns.

The study is candid about its limitations. The framework was validated on a single publicly available dataset, so cross-dataset and multi-institutional generalizability remain untested. Robustness against scanner variability, institutional differences, and varying noise conditions was not extensively evaluated. K-Means also assumes compact, roughly spherical clusters, which may not fully capture the complex, non-linear structures inherent in medical imaging data. And because the entire pipeline operates without clinical correlation or expert verification, direct medical interpretability remains limited. The clustering metrics measure computational separability, not diagnostic accuracy, and the authors explicitly warn that the identified groups should not be interpreted as clinically validated indicators of tumor severity or pathological grade.

The roadmap for future work is ambitious. The researchers plan to incorporate expert-annotated datasets containing pathological tumor grading, enabling them to test whether the latent imaging-pattern groups correspond to clinically validated grades when reviewed by medical professionals. They intend to explore probabilistic and density-based clustering methods, including Gaussian Mixture Models, DBSCAN, and spectral clustering, which may better model the messy distributions of real medical images. On the representation side, convolutional autoencoders, variational autoencoders, self-supervised learning, and contrastive representation learning are all on the table as ways to sharpen latent feature quality and cluster separability. The team also envisions integrating Explainable Artificial Intelligence techniques and quantitative tumor-region analysis to make the system’s groupings interpretable to clinicians.

What makes this work notable is its positioning within a broader shift in medical AI. As the authors note in their literature review, the field has been dominated by supervised deep learning, from CNN classifiers to VGG16-based hybrids and transformer models augmented with PCA, all of which demand extensive annotation. Unsupervised approaches like this one offer a complementary path: they can surface structure in unlabeled archives, flag candidate subgroups for expert review, and potentially reduce the annotation burden that has slowed clinical deployment of machine learning. By framing the output as exploratory imaging-pattern groups rather than diagnoses, the study models the kind of epistemic caution that unsupervised medical AI will need if it is ever to earn clinical trust. The work aligns with Sustainable Development Goal 3 on health and well-being and Goal 9 on industry, innovation, and infrastructure, and it suggests that even modest autoencoder architectures, when paired with careful validation, can extract genuine signal from the vast, unlabeled repositories of medical imaging data that hospitals accumulate every day.

Subject of Research: Unsupervised clustering of brain tumor MRI images using deep autoencoder embeddings and K-Means

Article Title: Unsupervised brain tumor MRI image grouping using deep autoencoder embeddings and K-means clustering

Article References: Arasavali, N., Gottapu, S., Sreelakshmi, K., Laveti, G., Nagothu, S. K., & Siddaraj, U. (2026). Unsupervised brain tumor MRI image grouping using deep autoencoder embeddings and K-means clustering. Discover Artificial Intelligence, 6(1), Article 1209. https://doi.org/10.1007/s44163-026-02241-9

Image Credits: AI Generated

DOI: 10.1007/s44163-026-02241-9

Keywords: brain tumor, MRI, autoencoder, K-Means clustering, unsupervised learning, medical imaging, t-SNE, Silhouette Score, PCA, VGG16, feature extraction, neuro-oncology

The clinical motivation behind the work is striking. Epidemiological and clinical studies suggest that patients with a history of stroke or traumatic brain injury face an increased risk of developing brain tumors, a risk that can be roughly three-fold to seven-fold depending on the age and sex of the patient. Yet despite these observations, the mechanism linking brain injury and cancer has remained unclear. The researchers set out to determine whether stroke actively promotes glioma growth and to uncover the factors mediating the connection, working with both human and mouse models.

First authors Dr. Qi Ye and graduate student Christine Madamba from the laboratory of corresponding author Dr. Hyun Kyoung Lee focused on stroke as the injury and glioma as the tumor. Glioma carries a devastating five-year survival rate, and the team found that stroke made its course even worse. In both human and mouse glioma models, stroke promoted tumor infiltration into injured brain regions and reduced overall survival. When the researchers examined the cellular and molecular makeup of the tumors more closely, they discovered that stroke triggers a remodeling of the tumor microenvironment, the complex ecosystem of cells and signals that surrounds and supports cancer cells.

At the heart of this remodeling was the emergence of a distinct population of brain cells called tumor-associated astrocytes, or TAAs. Astrocytes are star-shaped glial cells that normally support neurons by regulating blood flow, neurotransmitter uptake and the blood-brain barrier. In the stroke-injured tumor environment, however, astrocytes took on new physiological and molecular characteristics, including diminished calcium activity. Calcium signaling in astrocytes is a key communication channel that governs how these cells interact with their surroundings, and its reduction marked the TAAs as functionally distinct from their normal counterparts.

The TAAs did not act alone. The researchers observed that they were accompanied by the accumulation of two other cell types: remodeled tumor-associated microglia, the brain’s resident immune cells, and immune cells called macrophages, together known as tumor-associated macrophages or TAMs. Microglia and macrophages are known players in the brain’s response to injury, clearing debris and coordinating inflammation, but in this context they appeared to be recruited into a tumor-promoting alliance alongside the astrocytes.

The most consequential findings came from experiments that tested whether these cell populations were merely bystanders or active drivers of cancer progression. When the team restored calcium signaling in the tumor-associated astrocytes, or removed the TAMs, stroke-induced glioma progression was suppressed. These results identify both populations as critical mediators of the stroke response, proving that the injury-induced changes in the brain actively communicate with cancer cells and influence tumor behavior rather than simply marking time after damage.

The implications reach beyond glioma. Neuron-tumor interactions have previously been shown to contribute to cancer growth, but this study demonstrates that other brain cells, astrocytes, also seem to communicate with brain cancer cells and shape their behavior. As Lee notes, astrocytes should be considered when studying cancer mechanisms and therapies, adding to growing evidence pointing at a role for these glial cells in brain tumor growth. The work reframes the brain’s non-neuronal cells as active participants in cancer biology, not passive scaffolding.

Therapeutically, the findings suggest that the injury-induced, tumor-promoting pathways uncovered in this study are potential targets. If the astrocyte and macrophage responses that follow brain injury can be modulated, the risk of glioma growth in patients with a history of stroke or traumatic brain injury might be reduced. The researchers emphasize that this supports continuing research into strategies that could intervene in these pathways before tumors take advantage of the injured brain environment.

For patients and clinicians, the study provides a biological explanation for a clinical pattern that has long been observed but never mechanistically understood. Brain injury can now be considered a risk factor for brain cancer, and the cellular mediators of that risk, tumor-associated astrocytes with reduced calcium activity and tumor-associated macrophages, offer concrete starting points for prevention and treatment research. The work was a broad collaboration involving investigators from Baylor College of Medicine, Duncan NRI at Texas Children’s Hospital, Virginia Tech, Pennsylvania State University, Houston Methodist Research Institute, Weill Cornell Medical College, the University of Rhode Island and the University of Texas Health Science Center at Houston, among others, with first authors Qi Ye and Christine Madamba leading the experimental effort under Lee’s direction.

Subject of Research: Neuroscience and Cancer Research

Article Title: Researchers link brain injury to brain tumors

Article References: Researchers link brain injury to brain tumors. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, stroke, brain injury, brain tumor, astrocytes, tumor microenvironment, Nature Cancer, neuroscience, cancer research, Texas Children's Hospital, Researchers, link

A new randomized controlled trial published in Supportive Care in Cancer offers some of the clearest evidence to date that a structured, nurse-led program can change that picture. Researchers at the First Affiliated Hospital of Soochow University in Suzhou, China, enrolled 120 brain tumor patients with dysphagia admitted between January and May 2024, and randomly assigned them in stratified fashion to two groups of sixty. The control group received conventional nursing care and standard treatment protocols. The intervention group received a nurse-led multimodal program combining personalized swallowing training, nutritional support, psychological care, and a family-participatory rehabilitation component, designed and dynamically adjusted by a team of nurses, rehabilitation therapists, and dietitians.

The technical logic behind the intervention reflects a growing consensus in neurogenic dysphagia research: no single therapy works in isolation. Personalized swallowing training targets the motor patterns of the oropharyngeal phase, strengthening muscle groups and retraining the timing of the swallow reflex. Nutritional support addresses the caloric deficit and dehydration that accompany impaired swallowing, which otherwise accelerate physical decline and reduce the capacity for rehabilitation. Psychological care tackles the anxiety and social isolation that often make patients avoid eating altogether, while family participation extends therapy into daily life beyond the hospital ward, where most recovery actually happens.

To measure outcomes, the researchers used validated bedside assessments. The Kubota drinking test, in which patients swallow water under observation, screens for aspiration risk and functional swallowing capacity. Saito’s swallowing function grading provides a structured clinical classification of swallowing impairment severity. Quality of life instruments captured the broader patient experience. Before-and-after comparisons within each group were analyzed with paired t-tests or Wilcoxon signed-rank tests, while between-group differences were assessed using independent samples t-tests or the Mann-Whitney U test, depending on data distribution.

The results were unambiguous. Both groups improved over time, which is expected as patients recover and receive baseline care, but the intervention group improved significantly more. Scores on the Kubota drinking test, Saito’s grading, and the quality of life measures all showed statistically significant enhancement in the intervention group compared with the control group, with P values below 0.05. Within both groups, scores improved progressively as the intervention continued, but the trajectory of improvement was steeper for patients receiving the nurse-led program.

What makes this finding clinically important is the role assigned to nurses. In many hospitals, swallowing rehabilitation is initiated by speech-language pathologists or rehabilitation physicians, with nurses relegated to monitoring and medication delivery. This study flips that hierarchy, positioning nurses as the architects and coordinators of a multidisciplinary plan. Because nurses have the most continuous contact with patients, they are ideally placed to detect subtle changes in swallowing performance, adjust feeding strategies in real time, reinforce training exercises between formal therapy sessions, and coach family members who will support the patient after discharge.

The trial was prospectively registered at the Chinese Clinical Trial Registry on January 5, 2024, under registration number ChiCTR240001265, and was conducted in accordance with the Declaration of Helsinki with formal exemption approval from the hospital’s ethics committee. All participants provided written informed consent. The authors, Yaping Lu and Haifeng Wu of the Department of Neurosurgery, report no competing interests, and the study received no dedicated funding.

The broader context strengthens the case for this approach. Previous research has documented that dysphagia in brain tumor patients differs from post-stroke dysphagia in important ways, often involving tumor location in the posterior fossa, surgical sequelae, and the cumulative effects of radiation and chemotherapy on neural tissue. Studies of inpatient rehabilitation have shown that swallowing outcomes in this group can be meaningful but require sustained, coordinated effort. Meanwhile, a 2025 scoping review of rehabilitation nursing for brain tumor patients highlighted how fragmented care remains, and separate surveys from Saudi Arabia and low- and middle-income countries have revealed persistent gaps in nurses’ knowledge and practices around dysphagia screening and management.

Multimodal interventions have already shown promise in adjacent fields. A multi-center randomized controlled trial published in the International Journal of Nursing Studies in 2024 demonstrated that nurse-delivered stepwise swallowing training improved dysphagia in patients with Alzheimer’s disease. Individualized nutritional support has produced significant benefits in stroke patients with oropharyngeal dysphagia, and enhanced dysphagia assessment combined with dietary guidance has improved outcomes in post-stroke populations. The Soochow study extends this evidence base into neuro-oncology, a setting where rehabilitation needs have historically been overshadowed by the urgency of tumor treatment itself.

The authors conclude that nurse-led multimodal intervention is significantly effective in improving both swallowing function and quality of life in brain tumor patients, providing comprehensive rehabilitation support through multidisciplinary collaboration and personalized care, and carrying genuine clinical promotion value. For a patient population facing enormous therapeutic challenges, the message is quietly radical: recovery of something as fundamental as eating does not have to wait for a cure. With trained nurses orchestrating swallowing therapy, nutrition, psychological support, and family involvement, patients can reclaim a measure of dignity and health even in the midst of serious illness. As health systems worldwide grapple with growing neuro-oncology caseloads, this study suggests that one of the most effective tools may already be on the ward, wearing scrubs.

Subject of Research: Nurse-led multimodal rehabilitation of dysphagia in brain tumor patients

Article Title: Assessment of the role and effectiveness of nurse-led multimodal intervention in the rehabilitation of dysphagia in patients with brain tumors

Article References: Lu, Y., & Wu, H. (2026). Assessment of the role and effectiveness of nurse-led multimodal intervention in the rehabilitation of dysphagia in patients with brain tumors. Supportive Care in Cancer, 34(10), Article 953. https://doi.org/10.1007/s00520-026-11203-x

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11203-x

Keywords: brain tumor, dysphagia, swallowing rehabilitation, nurse-led intervention, randomized controlled trial, multimodal intervention, quality of life, nutritional support, neurogenic dysphagia, supportive cancer care, rehabilitation nursing, multidisciplinary care

The framework, developed by Sadaf Tabatabaee and Mohammad T. Khasawneh, was trained to distinguish glioma, meningioma, pituitary tumor, and no-tumor cases from contrast-enhanced T1-weighted MRI images. The corrected experimental cohort contained 7,023 images, split into 5,712 training images and 1,311 held-out test images, with data augmentation applied only to the training subset to reduce the risk of information leaking between splits. On the untouched test set, SYNAPSE-X achieved 98.41 percent accuracy, 98.2 percent macro-F1, and 98.4 percent weighted-F1 — figures comparable to the best convolutional and transformer-based pipelines previously reported on similar public four-class brain MRI datasets.

What sets the study apart is what happened next. The researchers point out that a model can be highly accurate on average yet dangerously overconfident in its errors, a phenomenon documented since Guo and colleagues showed in 2017 that modern neural networks are frequently miscalibrated. Calibration means that when a model says it is 90 percent sure, it should be right roughly 90 percent of the time on similar predictions. To measure this, the team used three complementary metrics: expected calibration error, which quantifies the gap between stated confidence and observed accuracy across confidence bins; the Brier score, a classical measure of how close predicted probabilities are to actual outcomes; and negative log-likelihood, which harshly penalizes confident mistakes.

Before any correction, SYNAPSE-X showed moderate calibration error despite its stellar accuracy. The team then applied temperature scaling, a simple post hoc technique that rescales the model’s raw output logits with a single learned parameter before the softmax function converts them into probabilities. Crucially, the temperature parameter was fitted only on a validation subset, never on the test data or the external cohort, preventing calibration leakage. The result was striking: expected calibration error fell from 0.041 to 0.018, a relative reduction of roughly 56 percent, while the Brier score dropped from 0.036 to 0.021 and negative log-likelihood fell from 0.092 to 0.061. Because temperature scaling only reshapes probability values and never changes which class the model picks, classification accuracy remained exactly the same — but the confidence numbers became genuinely meaningful.

With calibrated confidence in hand, the researchers implemented the framework’s most distinctive feature: selective referral. Instead of forcing every scan through the same automated decision pathway, predictions whose calibrated confidence fell below a threshold of 0.85 were flagged for expert review, while high-confidence predictions were retained for decision-support reporting. At this operating point, 93.3 percent of internal test cases were retained and 6.7 percent were referred to human specialists. Among the retained cases, accuracy rose to 99.12 percent, pushing retained-case risk below one percent. Sensitivity analyses across thresholds from 0.70 to 0.95 traced out the expected risk-coverage trade-off: more conservative thresholds reduced risk among retained cases but increased the referral burden on clinicians.

The error profile analysis added a clinically reassuring pattern. Referred and misclassified cases were not scattered randomly across the dataset; they clustered in categories where visual overlap is expected, particularly between glioma and meningioma, followed by meningioma and pituitary tumor. Meningioma showed the highest referral tendency, consistent with the fact that meningiomas can share enhancement patterns and boundary characteristics with other tumor types depending on location and imaging plane. No-tumor cases, by contrast, carried the lowest referral burden and the strongest high-confidence behavior. This suggests the model’s uncertainty is concentrated exactly where a radiologist would expect diagnostic difficulty — a property that makes confidence-based triage genuinely informative rather than arbitrary.

Perhaps the most demanding test came from outside the development data entirely. The trained model was applied, without any retraining, fine-tuning, architecture modification, external recalibration, or threshold re-selection, to an independent external brain MRI cohort of 3,264 images. Under this direct-transfer regime, SYNAPSE-X achieved 97.86 percent accuracy, 97.7 percent macro-F1, and 97.9 percent weighted-F1, with an external expected calibration error of just 0.026. At the same 0.85 referral threshold, the external referral rate was 8.4 percent and retained-case accuracy remained high at 98.74 percent. The modest performance drop relative to internal testing is exactly what dataset shift would predict, and the fact that calibration and referral behavior survived the transfer intact strengthens the case that the framework’s reliability signals are robust rather than artifacts of a single dataset.

The authors are careful to position the work honestly. Both the primary and external cohorts are public image-level datasets lacking complete patient-level identifiers, scanner metadata, and institutional acquisition information, which means patient-level independence could not be verified. The study is therefore framed as research-stage reliability assessment rather than clinical validation, and the external testing is described as direct-transfer evaluation rather than proof of deployment readiness. This cautious framing aligns with reporting guidelines such as CLAIM and TRIPOD+AI, and with a broader literature showing that radiology AI models often lose performance across hospital sites, sometimes because they learn site-specific acquisition signatures instead of genuine disease features. Distributional shift, prior work has shown, can degrade the reliability of confidence values themselves, not just accuracy — which is precisely why calibration-aware external testing matters.

Technically, the underlying classifier is a compact Vision Transformer in the tradition introduced by Dosovitskiy and colleagues, in which each 224-by-224 pixel MRI image is divided into non-overlapping 16-by-16 patches, producing 196 patch embeddings. Positional embeddings are added, and the sequence passes through transformer encoder blocks built on multi-head self-attention, residual connections, layer normalization, and feed-forward layers before a four-unit softmax head produces class probabilities. This architecture allows the model to capture not only local texture but also lesion shape and spatial context, which matters when tumor discrimination depends on relationships across distant image regions. Training used categorical cross-entropy loss, AdamW optimization with weight decay, dropout, and training-only augmentation, with checkpoint selection based on validation loss and macro-F1.

The broader significance of SYNAPSE-X lies in its conceptual shift. Conventional classification studies report one aggregate accuracy number, implicitly treating every prediction as equally dependable. By jointly evaluating accuracy, probability calibration, confidence-stratified correctness, risk-coverage behavior, and external transfer stability, the framework converts brain tumor MRI classification into a reliability-aware selective-referral problem in which the AI acts as a triage-aware assistant rather than an infallible oracle. The authors suggest that future work should move to patient-level, multi-institutional datasets with scanner diversity, prospective evaluation, and radiologist-in-the-loop studies to determine whether calibrated selective referral can support safe clinical workflows. For now, the study offers a compelling demonstration that the next generation of medical AI may be judged not by how often it is right, but by how honestly it communicates the moments when it is not sure.

Subject of Research: Calibration-aware Vision Transformer classification of brain tumor MRI with uncertainty-guided selective referral

Article Title: SYNAPSE-X: a calibration-aware vision transformer framework for selective referral in multi-class brain tumor MRI classification

Article References: Tabatabaee, S., & Khasawneh, M. T. (2026). SYNAPSE-X: a calibration-aware vision transformer framework for selective referral in multi-class brain tumor MRI classification. Neural Computing and Applications, 38(20), Article 813. https://doi.org/10.1007/s00521-026-12608-9

Image Credits: AI Generated

DOI: 10.1007/s00521-026-12608-9

Keywords: brain tumor, MRI, Vision Transformer, deep learning, calibration, temperature scaling, selective referral, uncertainty quantification, medical imaging, risk-coverage analysis, external validation, decision support

A new retrospective cohort study from a team of Italian neurosurgeons, neurologists, and neuroradiologists led by Francesco Guerrini of Fondazione IRCCS Policlinico San Matteo in Pavia offers a fresh clue. Published in the Journal of Neuro-Oncology, the research examines whether the shape of a lesion visible on postoperative diffusion-weighted imaging—DWI for short—can tell clinicians which patients are most likely to experience neurological worsening after eloquent-area glioma surgery. The answer, the researchers suggest, is more nuanced than a simple yes or no.

DWI is a magnetic resonance imaging technique that detects regions where water molecules cannot move freely, a hallmark of acute ischemic injury. When brain tissue is deprived of blood flow, cells swell and restrict the diffusion of water, producing a bright signal on DWI scans. For years, neurosurgeons have used postoperative DWI to identify silent strokes or small infarcts that might explain why a patient’s speech slurred or a limb weakened after tumor removal. But the technique has limitations. Bright spots on DWI do not always correspond to clinical deficits, and many patients who worsen neurologically show no obvious ischemic lesion at all.

The Italian team hypothesized that the morphology of these postoperative DWI lesions might matter. They classified lesions into two categories: sector-shaped, which appear as wedge-like areas of restricted diffusion, and rim-shaped, which form thin borders around the surgical cavity. Sector-shaped lesions, the researchers reasoned, might represent true arterial infarcts—blocks of tissue deprived of blood supply—while rim-shaped lesions could reflect a different phenomenon, perhaps related to surgical manipulation of the cortex surrounding the resection cavity rather than a genuine vascular occlusion.

To test this, the investigators analyzed 139 consecutive patients who underwent resection of supratentorial gliomas in eloquent areas, all classified as World Health Organization grade 2 through 4. Each patient received a postoperative MRI within 48 hours of surgery, allowing the team to categorize any DWI lesion by its shape. Neurological status was assessed at discharge and again at a follow-up visit four to six months later, providing both an early and a delayed picture of functional outcome.

The results were striking. DWI lesions appeared in 44 of the 139 patients, or 31.7 percent of the cohort. Of these, 31 were sector-shaped and 13 were rim-shaped. Overall, 59 patients—42.4 percent of the entire group—experienced neurological worsening at discharge. When the researchers looked at DWI positivity alone, without considering lesion shape, they found no significant association with worsening. But when they broke the lesions down by morphology, a clear pattern emerged. Sector-shaped DWI lesions were strongly associated with neurological decline, carrying a positive predictive value of 58.1 percent. In other words, if a patient had a wedge-shaped lesion on their postoperative scan, there was a better-than-even chance they would worsen neurologically. After adjusting for other variables in a multivariable model, sector-shaped lesions remained independently associated with worsening, with an odds ratio of 3.83. The confidence interval, however, was wide—ranging from 1.30 to 11.29—reflecting the modest sample size and suggesting that while the signal is real, its precise magnitude remains uncertain.

Rim-shaped lesions told a different story. These thin borders of restricted diffusion carried a positive predictive value of only 38.5 percent, which was essentially indistinguishable from the 37.9 percent risk of worsening observed in patients whose postoperative DWI was entirely negative. In a direct comparison between the two morphologies, the difference did not reach statistical significance, though the trend favored the idea that sector-shaped lesions are the more clinically meaningful finding. This distinction matters because it suggests that not all bright spots on a postoperative DWI scan are created equal. A rim of restricted diffusion hugging the cavity wall may be a benign epiphenomenon of surgery, while a wedge-shaped lesion in the territory of a perforating artery may signal a true ischemic event with real functional consequences.

Perhaps the most sobering finding of the study is what it reveals about the limits of DWI itself. Sixty-one percent of all neurological worsening in this cohort occurred in patients whose postoperative scans showed no DWI lesion whatsoever. This means that the majority of early postoperative decline after eloquent-area glioma surgery cannot be explained by ischemia visible on DWI. The researchers suggest that non-ischemic mechanisms—such as mechanical manipulation of subcortical pathways, edema, vascular dysregulation, or transient metabolic disruption—may be responsible. This finding aligns with a growing body of literature suggesting that surgically acquired deficits often arise from disruption of white matter tracts rather than from overt stroke, and it underscores the need for imaging modalities or biomarkers that can detect these subtler forms of injury.

The study also identified two additional factors associated with neurological outcome. Awake craniotomy, a technique in which the patient is woken during surgery to perform language or motor tasks, was independently associated with worsening, a finding that may reflect the inherent difficulty of operating in eloquent cortex rather than a flaw in the technique itself. Meanwhile, tumors located in the frontal lobe carried a lower risk of worsening compared with those in other eloquent regions, possibly because frontal language and motor networks possess greater redundancy or because surgical corridors in the frontal lobe are more forgiving. At the four-to-six-month follow-up, only nine patients—6.5 percent of the cohort—still had a deficit, and all of them had IDH-wildtype glioblastoma, the most aggressive and least metabolically favorable glioma subtype. Persistent deficit was also associated with a decrease of at least 50 percent in intraoperative evoked potentials, a neurophysiological monitoring signal that reflects the integrity of motor or sensory pathways during surgery.

These findings carry important implications for the field of neuro-oncology. First, they suggest that radiologists and surgeons should pay close attention to lesion morphology when interpreting postoperative DWI in glioma patients, rather than simply reporting the presence or absence of restricted diffusion. A sector-shaped lesion warrants closer clinical scrutiny, while a rim-shaped lesion may be less alarming than its appearance suggests. Second, the high proportion of worsening without DWI ischemia reinforces the idea that function-guided surgery—whether performed awake or asleep—exerts its effects on the brain through mechanisms that standard MRI cannot fully capture. Third, the association between persistent deficit and IDH-wildtype glioblastoma highlights the biological differences between glioma subtypes and suggests that patients with these aggressive tumors may have less capacity for functional recovery after surgery. Finally, the authors caution that their findings require confirmation in larger, prospective series, given the retrospective design, the modest number of patients with each lesion morphology, and the wide confidence intervals around some of their estimates. Still, the study represents a meaningful step toward a more refined understanding of what happens to the brain during eloquent-area glioma surgery, and it offers clinicians a new lens—quite literally—through which to interpret the postoperative scan.

Subject of Research: Postoperative diffusion-weighted imaging lesion morphology and neurological outcome after eloquent-area glioma surgery

Article Title: Postoperative DWI morphology and neurological worsening after eloquent-area glioma surgery: a retrospective cohort study

Article References: Guerrini, F., D’Agata, F., Musella, V., Vitali, A., Giuri, A., Caporrimo, M. C., Chiapparini, L., & Spena, G. (2026). Postoperative DWI morphology and neurological worsening after eloquent-area glioma surgery: a retrospective cohort study. Journal of Neuro-Oncology, 180(2), Article 23. https://doi.org/10.1007/s11060-026-05837-4

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05837-4

Keywords: glioma surgery, diffusion-weighted imaging, DWI lesion morphology, eloquent cortex, neurological worsening, awake craniotomy, intraoperative neurophysiology, postoperative MRI, IDH-wildtype glioblastoma, surgical outcomes, neuro-oncology, brain tumor

The team, led by Rashmitha R. Nayak and B. N. Anoop, tackled a problem that has long fragmented the field of medical image analysis. Most previous studies have treated tumor classification and tumor segmentation as separate challenges, and explainability tools have typically been bolted on afterward rather than woven into the diagnostic workflow. The new framework integrates three components into one system: an ensemble classifier that decides whether a scan shows a glioma, meningioma, pituitary tumor, or healthy tissue; a three-dimensional U-Net that traces the exact extent of the tumor; and Grad-CAM visualizations that highlight which parts of the image drove the model’s decision.

The classification engine is built on two well-known convolutional neural network architectures, DenseNet121 and InceptionV4, combined through a technique called soft voting. DenseNet121 uses a dense connectivity pattern in which every layer receives inputs from all preceding layers, encouraging feature reuse and stable gradient flow during training. InceptionV4, a deeper member of the Inception family, balances computational cost and representational power through carefully factorized convolutional blocks and residual connections. Rather than forcing a choice between them, the ensemble averages the probability distributions each model assigns to the four diagnostic categories and selects the class with the highest combined score. The intuition is simple: two networks that see the image differently are less likely to make the same mistake.

The numbers back that intuition up. On a held-out test set drawn from a publicly available Kaggle dataset of 7,023 grayscale MRI images, the ensemble achieved 98.52 percent accuracy, edging out InceptionV4 at 98.28 percent, DenseNet121 at 97.93 percent, and a lightweight custom CNN baseline at 95.00 percent. Per-class precision, recall, and F1-scores were consistently high, with a macro-averaged F1 of roughly 0.98, indicating that the model performed well across all four categories rather than excelling on common classes while neglecting rare ones. Receiver operating characteristic analysis reinforced the picture, with macro and micro AUC values approaching 1.0 for the transfer learning models and the ensemble.

The researchers were careful about statistics, running stratified five-fold cross-validation to tune hyperparameters and then applying a Friedman test to the fold-wise accuracies. That test confirmed a statistically significant difference among the four classifiers, with the ensemble consistently ranked first. Pairwise Wilcoxon signed-rank tests, however, did not reach significance, a limitation the authors attribute to the small number of folds, which constrains the statistical power of non-parametric comparisons even when the ranking is stable. Cross-validation standard deviations of just 0.03 to 0.08 percentage points suggested that both flagship networks behave consistently across data splits.

Classification alone tells a clinician what a tumor probably is; segmentation shows where it is. For that second task, the team trained a 3D U-Net on the BraTS 2020 dataset, a collection of multimodal MRI volumes with expert-annotated tumor masks. Each subject’s scans included T1, T1-contrast, T2, and FLAIR sequences, of which the researchers used the latter three as input channels. The U-Net’s encoder-decoder structure, connected by symmetric skip connections, lets the network capture both high-level context and fine spatial detail, and a final sigmoid layer produces a voxel-wise probability map of the whole tumor region. The authors simplified the problem to binary segmentation by merging the enhancing tumor, tumor core, and whole tumor subregions into a single foreground class.

Training the segmentation network required a loss function tailored to the peculiar challenges of medical imaging, where tumor voxels are vastly outnumbered by healthy tissue. The team combined binary Dice loss and focal loss in equal measure, a hybrid designed to maximize spatial overlap while down-weighting the easy background examples that would otherwise dominate the gradient signal. The resulting model achieved a Dice similarity coefficient of 0.8423 and an Intersection over Union of 0.7497 on the independent test set of 105 MRI volumes. Qualitative inspection showed close agreement with ground-truth annotations for larger, well-defined tumors, while small or diffuse boundaries remained harder, a difficulty familiar from prior BraTS studies.

Perhaps the most clinically significant element is the framework’s insistence on showing its work. Deep networks are often dismissed as black boxes, and clinicians are rightly reluctant to trust a diagnosis they cannot interrogate. By applying Grad-CAM, which uses the gradients flowing into the final convolutional layer to produce heatmaps of influential image regions, the researchers demonstrated that their models consistently attended to tumor-relevant anatomy rather than spurious artifacts. Notably, the ensemble produced more focused attention maps than its individual members, while the simpler custom CNN spread its attention more broadly, mirroring its lower accuracy. The heatmaps offer radiologists visual evidence that the machine is looking at the same suspicious mass they are.

The authors are candid about the study’s limits. The classification and segmentation components were trained on two different public datasets, so the complete workflow has not yet been validated end-to-end on a single dataset carrying both labels and segmentation masks. All evaluation used public data, leaving generalisability to other institutions, scanners, and imaging protocols untested, and Grad-CAM, while informative, does not fully explain a network’s decision process. The framework has also not been deployed in real clinical workflows. Future work, the team says, will explore unified multi-task datasets, multi-centre validation, transformer-based and hybrid CNN-Transformer architectures, uncertainty estimation, and more advanced explainable AI techniques.

Even with those caveats, the study offers a compelling glimpse of where computer-aided diagnosis is heading: not a single oracle model, but an integrated pipeline that classifies, localizes, and justifies its conclusions. With the source code openly available on GitHub and both datasets publicly accessible, the work lowers the barrier for other groups to reproduce, critique, and extend it. As the authors put it in their conclusion, the results demonstrate the potential of deep learning systems to help radiologists achieve faster, more accurate, and more reliable brain tumor diagnosis — provided the machines can earn the same trust that human experts spend decades building.

Subject of Research: Deep learning framework for automated brain tumor classification, segmentation, and explainability in MRI

Article Title: Automated classification and segmentation of brain abnormalities using deep learning approaches in brain MRI

Article References: Nayak, R. R., Ramyashree, Raghavendra, S., & Anoop, B. N. (2026). Automated classification and segmentation of brain abnormalities using deep learning approaches in brain MRI. Discover Artificial Intelligence, 6(1), Article 1260. https://doi.org/10.1007/s44163-026-02253-5

Image Credits: AI Generated

DOI: 10.1007/s44163-026-02253-5

Keywords: brain tumor, MRI, deep learning, convolutional neural networks, ensemble learning, DenseNet121, InceptionV4, U-Net, image segmentation, Grad-CAM, explainable AI, computer-aided diagnosis

The research, conducted at Aalborg University Hospital in collaboration with Aarhus University Hospital and published in Frontiers in Neuroimaging, compared gadolinium-based contrast agent-free (GBCA-free) MRI against the full contrast-enhanced protocol in a real-world diagnostic pathway. The team included 191 patients harboring 195 intracranial tumors—124 intra-axial, arising within brain tissue itself, and 71 extra-axial, growing outside the brain parenchyma—alongside 410 randomly selected controls drawn from nearly 2,000 patients referred with suspected brain tumors between 2013 and 2022. The design mirrored the clinical reality of the North Denmark Region, where patients meeting national criteria for possible brain tumors are referred directly for MRI, typically within six days.

Three senior neuroradiologists independently reviewed anonymized scans, blinded to all clinical and demographic information. Each scan was first evaluated using only GBCA-free sequences: axial diffusion-weighted imaging with b-values of 0 and 1,000, sagittal T2-weighted imaging, and coronal T2-FLAIR. These sequences exploit the biophysical signatures of tumors—restricted water diffusion in densely cellular masses, prolonged T2 relaxation in edematous tissue, and abnormal signal on FLAIR that suppresses cerebrospinal fluid to highlight lesions near fluid-filled spaces. Only afterward were the same readers shown the complete dataset, now including T1-FLAIR images acquired seven and ten minutes after injection of 0.2 milliliters per kilogram of gadoteridol, in a randomized order designed to prevent recall bias.

The results upended expectations. GBCA-free MRI achieved a sensitivity of 79.6 percent and a specificity of 96.1 percent across the combined evaluation of all three raters. The contrast-enhanced protocol, traditionally considered the gold standard, performed slightly worse: a sensitivity of 73.3 percent and a specificity of 92.9 percent. The difference was not statistically significant, with a p-value of 0.15 and an odds ratio of 1.706 whose 95 percent confidence interval spanned 1. Agreement between the two approaches was substantial, measured by Cohen’s kappa at 0.699—a level of concordance that indicates the two methods reliably identify the same patients as tumor-positive or tumor-negative.

Subgroup analyses revealed comparable performance for intra-axial tumors, where GBCA-free imaging reached a sensitivity of 79.0 percent and specificity of 98.5 percent, outpacing the contrast-enhanced protocol’s 74.2 percent and 96.2 percent. For extra-axial tumors, both modalities showed modest sensitivity—56.3 percent for GBCA-free and 57.8 percent for contrast-enhanced—despite high specificity above 95 percent. The authors attribute these lower rates partly to the absence of clinical context during the blinded review: without knowing the patient’s symptoms or having access to prior imaging, radiologists were less inclined to label ambiguous hyperintensities as neoplastic. In routine practice, interpretation is embedded in a multidisciplinary discussion that typically raises detection rates.

The slightly superior sensitivity of the non-contrast approach may seem counterintuitive, but the authors propose a known perceptual pitfall as a possible explanation. When radiologists begin by examining contrast-enhanced sequences and find no abnormal enhancement, their detection efficiency for the non-contrast images that follow can decline—a phenomenon related to the satisfaction of search error, which occurs in roughly 22 percent of diagnostic radiology. Conversely, when readers start with diffusion-weighted and T2-FLAIR images, cellular tumor components and associated ischemic changes can appear more conspicuous than subtle gadolinium enhancement, particularly when the images are evaluated without clinical context.

The findings align with earlier work suggesting that non-contrast protocols can be diagnostically powerful. A 2010 study combining high-resolution susceptibility-weighted imaging with apparent diffusion coefficient maps accurately diagnosed tumor pathology in 52 of 73 brain tumors, and a 2024 nonsystematic review of 51 articles concluded that reduced doses of gadolinium could be considered in initial diagnostics and that contrast could be skipped entirely in postoperative follow-up of meningiomas. The Danish study extends this evidence by testing the concept at scale within an actual regional diagnostic pathway rather than in a controlled research setting.

From a health-economic perspective, the implications are substantial. In large screening pathways, the majority of referred patients ultimately turn out not to have tumors. Administering gadolinium to every one of them carries cost, adds examination time, and exposes thousands of patients to a heavy metal they may not need. Reserving contrast-enhanced imaging for cases requiring further lesion characterization—small metastases, leptomeningeal disease, or subtle masses that demand T1 enhancement for optimal visualization—could yield significant resource savings while maintaining diagnostic accuracy. The approach also eliminates the risk of immediate hypersensitivity reactions to gadolinium-based agents and removes the need to assess renal function before every scan, simplifying workflow in high-volume settings.

The study has acknowledged limitations. Each scan was reviewed by only one neuroradiologist, precluding formal inter-rater reliability analysis. The two-dimensional sequences with 5-millimeter slice thickness reflect the imaging standards of the 2013–2022 study period; contemporary neuro-oncological imaging often employs high-resolution three-dimensional post-contrast sequences with isotropic voxels that may improve detection of small lesions. Tumor size, lesion multiplicity, and subtype were not analyzed, and a post-hoc precision assessment indicated that while the study was adequately powered for specificity estimates, larger cohorts of 250 to 301 tumor cases would have been needed for equally precise sensitivity estimates. The retrospective design may also introduce selection biases that prospective validation would address.

Looking forward, the authors encourage research into tailored imaging protocols based on tumor subtype and clinical presentation, and they point to emerging artificial intelligence tools as a potential force multiplier. AI-assisted analysis of T2-FLAIR and diffusion-weighted images could enhance sensitivity for small or extra-axial tumors, further optimizing GBCA-free screening. For now, the message from Denmark is clear: when it comes to first-line screening for intracranial tumors, the contrast agent may be a luxury the brain can do without.

Subject of Research: Gadolinium-based contrast agent-free (GBCA-free) versus gadolinium-based contrast agent-enhanced (GBCA-enhanced) magnetic resonance imaging as a screening tool for intracranial tumors

Article Title: Gadolinium-based contrast agent-free (GBCA-free) versus gadolinium-based contrast agent-enhanced (GBCA-enhanced) magnetic resonance imaging as a screening tool for intracranial tumors

Article References: Al-Rubaiee, H. F. H., Al-Salm, S. A. A., Jensen, W., Delekta, A. M., Yavarian, Y., & Modrau, B. (2026). Gadolinium-based contrast agent-free (GBCA-free) versus gadolinium-based contrast agent-enhanced (GBCA-enhanced) magnetic resonance imaging as a screening tool for intracranial tumors. Frontiers in Neuroimaging, 5, Article 1776934. https://doi.org/10.3389/fnimg.2026.1776934

Image Credits: AI Generated

DOI: 10.3389/fnimg.2026.1776934

Keywords: MRI, gadolinium, brain tumor, neuroradiology, medical imaging, Gadolinium-based, contrast, agent-free, GBCA-free, versus, agent-enhanced, GBCA-enhanced

The technique belongs to a field called quantitative ultrasound, or QUS. Conventional B-mode ultrasound, the grayscale image familiar from maternity wards and emergency rooms, displays anatomy but says little about what the tissue is actually made of at the microscale. QUS goes a step further by treating the raw backscattered radiofrequency signal as data. When an ultrasound pulse travels into tissue, it scatters off microscopic structures such as cells, vessels, and extracellular fibers. The amplitude of the returning echo, known as the envelope, carries a statistical fingerprint of those scatterers: their density, their spatial organization, and their clustering. By fitting probability distributions to the envelope, researchers can extract numbers that correlate directly with tissue microstructure, numbers that a standard grayscale image simply cannot provide.

The team evaluated three complementary statistical models. The Homodyned-K distribution, the most general of the three, separates the echo into a coherent component, arising from periodically arranged scatterers, and a diffuse component, arising from randomly distributed ones. Its parameter alpha describes scatterer clustering, while a derived parameter k captures the ratio of coherent to diffuse signal power. The Nakagami distribution, a simpler model, uses a shape parameter m that reflects the effective number density of scatterers and a scale parameter Omega related to backscattered energy. The Burr distribution, the newest addition to the envelope-statistics toolkit, assumes that scatterers exhibit multi-scale, power-law behavior, making it sensitive to fractal and elongated structures such as the branching vascular networks and fibrillar collagen that characterize tumors. Its shape parameter b reflects the density of fractal scattering structures, while its scale parameter lambda relates to echo amplitude.

To test whether these statistics could distinguish tumor from healthy tissue, the researchers worked with forty human tissue samples, twenty glioblastoma specimens resected from patients aged 15 to 68 and twenty normal brain samples obtained from the NIMHANS brain bank. Because surgeons cannot safely remove healthy brain tissue during tumor surgery, the control specimens came from post-mortem donations collected within 24 hours. Each sample, fixed in formalin and cut into blocks a few millimeters thick, was embedded in a solidified agarose phantom to hold it steady during imaging. A fraction of every sample was processed for histopathology, and two experienced neuropathologists with 10 and 25 years of experience independently confirmed the diagnoses, providing a ground truth against which the ultrasound statistics could be validated.

Ultrasound data were acquired with a Verasonics Vantage 128 research system driving a linear array transducer at a center frequency of 7.6 megahertz, focused 14 millimeters into each sample. Five independent imaging planes were collected per specimen, with the transducer translated by roughly one millimeter between acquisitions, a distance greater than the lateral beamwidth, ensuring that consecutive measurements sampled genuinely different regions of tissue. Before any statistics were computed, the team measured the frequency-dependent acoustic attenuation of the samples using a broadband pulse-echo insertion-loss technique with a separate 20-megahertz single-element transducer. Because formalin fixation and tissue composition alter how sound is absorbed as it propagates, the raw radiofrequency data were compensated for attenuation in the frequency domain before envelope analysis, preventing absorption artifacts from masquerading as microstructural differences.

The results were striking. Every parameter from all three distributions differed significantly between glioblastoma and normal brain. The HK clustering parameter alpha was higher in tumor tissue, while the coherent-to-diffuse ratio k was lower, indicating increased scatterer clustering together with a greater contribution of diffuse scattering, findings that align with the necrotic zones and microvascular proliferation visible under the microscope. The Nakagami parameters m and Omega were both elevated in tumor samples, reflecting a higher effective density of scatterers and greater backscattered energy, consistent with the dense, pleomorphic tumor cells and high nuclear-to-cytoplasmic ratios of glioblastoma. The Burr parameters b and lambda were also higher in tumor tissue, suggesting that the tumor’s fractal vessel networks and its remodeling of the extracellular matrix, with increased deposition of fibrillar collagens, fibronectin, and laminin, create elongated, anisotropic scattering sites that produce heavy-tailed echo amplitudes. Effect sizes were medium to large for most parameters, with Cohen’s d values exceeding 1.0 for several, indicating robust group separation.

The researchers then fed these features into machine learning classifiers, including logistic regression, linear support vector machines, random forests, and multilayer perceptron neural networks. Performance was assessed at two levels: per-sample, where the five imaging planes were averaged into a single observation per specimen, and per-plane, where each image counted as an independent observation. To avoid optimistic bias, the team used leave-one-out cross-validation for per-sample analysis and group K-fold cross-validation for per-plane analysis, ensuring that planes from the same specimen never appeared in both training and test sets. Hyperparameters were tuned with the Optuna framework, and a stricter nested cross-validation was also performed. Among individual distributions, HK-derived features achieved the highest single-model performance at 90.0 percent per-sample accuracy. Combining all six features pushed the linear SVM to 97.5 percent per-sample accuracy with an area under the receiver operating characteristic curve of 0.985, and a reduced four-feature subset, dropping the scale parameters, achieved comparable results, indicating that shape-related parameters carry most of the discriminative information.

Per-plane classification, a tougher test because individual imaging planes capture localized heterogeneity within a sample, still reached 80.5 percent accuracy with an AUC of 0.854 using the six-feature set. Under nested cross-validation, the strictest evaluation, per-sample accuracy decreased to 90.0 percent, a reduction consistent with the optimistic bias expected when model selection and evaluation share the same data splits, but the overall performance trends across feature subsets remained unchanged. Feature importance analysis using random forests identified the HK clustering parameter alpha and the Nakagami scale parameter Omega as the most discriminative features, underscoring the central role of scatterer organization and backscattered energy in telling tumor from healthy tissue. Notably, increasing model complexity did not consistently improve performance, suggesting that the envelope statistics features are largely separable with simple, interpretable decision boundaries, an encouraging property for any future clinical deployment.

The authors are careful to frame this as proof of concept rather than a ready-made clinical tool. Formalin fixation alters acoustic properties relative to fresh tissue, with previous studies reporting attenuation changes ranging from minus 29 to plus 55 percent after fixation, although because both tumor and control samples were fixed under identical conditions, the relative trends are likely to remain valid. The tumor and control cohorts also came from different sources, with potential confounds in post-mortem interval, handling, age distribution, and sex balance, and the dataset of forty samples was imbalanced toward males. Attenuation compensation relied on group-specific average coefficients rather than sample-specific measurements, which could not be obtained for all tissues due to limited dimensions and insufficient signal-to-noise ratio. The authors also note that whole-region parameter averages do not capture spatial heterogeneity within individual samples, a limitation for margin assessment where local variation is exactly what matters.

Even so, the study opens a genuinely exciting translational path. Because ultrasound is cheap, portable, and already standard in neurosurgical operating rooms, a multiparametric envelope-statistics framework could one day complement conventional B-mode imaging by overlaying quantitative microstructural maps onto the surgeon’s view, helping delineate tumor margins in real time without the expense of intraoperative MRI or the limited sensitivity of fluorescence-guided resection. The researchers envision next steps using freshly excised tissues and, ultimately, in-situ examination of brain tumors in patients with a specialized intraoperative probe. If those studies succeed, the statistical whisper of scattered ultrasound echoes, invisible in a grayscale image, could become a powerful new voice in the fight against one of medicine’s most formidable cancers.

Subject of Research: Science

Article Title: Ultrasound echo envelope statistics to differentiate glioblastoma multiforme from normal brain tissue ex vivo: a proof-of-concept study

Article References: Patil, J. M., Agarwal, M., Rao, S., Vazhayil, V., Pandya, H. J., Mahadevan, A., Shekhar, H., & Mercado-Shekhar, K. P. (2026). Ultrasound echo envelope statistics to differentiate glioblastoma multiforme from normal brain tissue ex vivo: a proof-of-concept study. Frontiers in Acoustics, 4, Article 1882624. https://doi.org/10.3389/facou.2026.1882624

Image Credits: AI Generated

DOI: 10.3389/facou.2026.1882624

Keywords: glioblastoma, quantitative ultrasound, envelope statistics, machine learning, tumor margins, medical imaging, brain tumor, Ultrasound, echo, envelope, statistics, differentiate

The study reviewed patients diagnosed with tissue-confirmed central neurocytoma between 1990 and 2025 across the two institutions. Fifty-one patients made up the final cohort, with a median age at diagnosis of just 26 years and a remarkable median follow-up of 9.7 years, a duration that few single-institution series of this rare tumor have achieved. That long observational window matters enormously for a tumor that can recur years, even decades, after initial treatment. The researchers calculated recurrence-free survival and overall survival using Kaplan-Meier methods, the standard statistical approach for tracking how many patients remain free of disease over time, and then applied multivariate Cox regression analysis to a pre-planned set of variables to determine which factors independently influenced the risk of the tumor coming back.

The headline survival numbers remain genuinely encouraging. Overall survival for the entire cohort stood at 94 percent at ten years, meaning that despite the tumor’s location in a surgically treacherous part of the brain and its tendency to recur, death from this disease is uncommon. Central neurocytomas sit within or adjacent to the lateral ventricles, the cavities that produce and circulate cerebrospinal fluid, and surgery there carries risks of hydrocephalus, bleeding, and injury to deep brain structures. Yet the long-term mortality data confirm that for most patients, this is a disease to be managed rather than feared, provided that recurrences are caught and treated promptly.

Recurrence, however, proved to be a much more common companion than the field has generally acknowledged. Among patients who did not receive adjuvant radiotherapy after surgery, the five-year recurrence-free survival was 61 percent following gross total resection, the operation in which the surgeon removes all visibly identifiable tumor, versus 46 percent after subtotal resection, where some tumor is deliberately or unavoidably left behind. The difference between the two surgical outcomes did not reach statistical significance in this cohort, with a P value of 0.18, but the absolute numbers are striking. A 39 percent chance of recurrence within five years after a supposedly complete removal contradicts the widely held assumption that gross total resection alone is curative, and it directly challenges previous reports that have portrayed recurrence after complete surgery as an exception rather than a rule.

The multivariate analysis sharpened the picture by isolating four independent predictors of worse recurrence-free survival. Omission of adjuvant radiotherapy carried a hazard ratio of 9.0, meaning patients who did not receive postoperative radiation were nine times more likely to experience recurrence, with a P value of 0.003. Subtotal resection carried a hazard ratio of 5.7, statistically significant at P equals 0.017. Younger age at diagnosis was associated with a hazard ratio of 3.1, significant at P equals 0.002, an intriguing finding suggesting that the biology of these tumors in younger patients may be more aggressive than their histological appearance implies. Finally, a higher Ki-67 proliferation index, a pathologist’s measure of how many tumor cells are actively dividing, carried a hazard ratio of 1.13 per unit increase, significant at P equals 0.017, confirming that the biological activity of the tumor itself, not merely the extent of surgery, shapes the risk of relapse.

The Ki-67 finding deserves particular attention because it connects this study to a long-running debate in neuropathology. Ki-67 is a protein expressed by cells in the active phases of the cell cycle, and the labeling index, the percentage of tumor nuclei that stain positive for it, has been used for decades to distinguish indolent from more aggressive gliomas. For central neurocytomas, earlier work had suggested that tumors with elevated MIB-1 labeling, the antibody used to detect Ki-67, behave more aggressively and deserve the designation of atypical neurocytoma. The new multi-institutional data lend substantial statistical weight to that idea, showing that even within a WHO grade 2 classification, the proliferative index carries real prognostic information that should inform how closely a patient is monitored and whether additional therapy is considered up front.

Perhaps the most clinically actionable result concerns what happens after the first recurrence. Among the 17 patients in the cohort who received salvage radiotherapy, radiation delivered at the time of their first relapse rather than immediately after initial surgery, the five-year recurrence-free survival after that salvage treatment was 83 percent, with a median follow-up of 4.8 years. In other words, holding radiation in reserve until the tumor actually returns produced durable long-term control for the large majority of patients. This strategy, sometimes called deferred or salvage treatment, spares patients the potential toxicities of brain radiotherapy, which can include cognitive effects and injury to surrounding healthy tissue, during the years when they are most likely to be building careers and families. For a tumor diagnosed at a median age of 26, deferring radiation without compromising ultimate control is a meaningful quality-of-life win.

The findings arrive amid a broader re-evaluation of how central neurocytomas should be managed. Recent multicenter studies from Korea and France have reported improved tumor control with adjuvant radiotherapy, and an earlier 35-year experience from the Mayo Clinic itself had generated management recommendations favoring consideration of postoperative radiation in selected cases. The new study builds on that foundation with longer follow-up and a formal multivariate framework, and its results suggest a middle path: patients with favorable features, such as a gross total resection, a low Ki-67 index, and older age at diagnosis, may be safely observed with close surveillance imaging, while those with subtotal resections, high proliferative indices, or young age warrant a serious discussion about adjuvant radiotherapy given the ninefold increase in recurrence risk when it is omitted.

There are important caveats to keep in view. Fifty-one patients, though large for this ultra-rare tumor, is still a modest number, and the comparison between adjuvant radiotherapy and observation was not randomized; treatment decisions were made by clinicians and patients over three and a half decades, raising the possibility of selection bias in who received radiation. The hazard ratios, while statistically significant, come from retrospective data, and the authors themselves note that no new datasets were generated or analyzed beyond the clinical records reviewed. The difference in five-year recurrence-free survival between gross total and subtotal resection without radiotherapy did not reach significance, a reminder that even apparent clinical differences in rare-disease cohorts require cautious interpretation. Still, the consistency of the Ki-67 and age findings with prior literature strengthens the case that they reflect genuine biology rather than statistical noise.

For the young patients who make up the vast majority of those diagnosed with central neurocytoma, the practical message of this study is one of informed vigilance rather than alarm. Survival is excellent, ten-year mortality is low, and even tumors that return can usually be brought back under control with salvage radiotherapy. But the era of assuming that a clean surgical margin equals a cure appears to be over. The study’s authors, led by Yufan Yang of the University of Michigan and Northwestern University’s radiation oncology team together with colleagues at the Mayo Clinic, argue that their cohort represents one of the most comprehensive long-term pictures of this disease available anywhere. As molecular profiling increasingly refines the classification of even rare brain tumors, the proliferative index and the patient’s age at diagnosis are emerging as the numbers that matter most, and clinicians managing these tumors now have firmer statistical ground on which to decide who needs radiation now and who can safely wait.

Subject of Research: Long-term recurrence outcomes and prognostic predictors in central neurocytoma

Article Title: Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience

Article References: Yang, Y., Leenstra, J. L., Brown, P. D., Wadhwani, N., Ho, A., & Sachdev, S. (2026). Long term outcomes and predictors of recurrence in central neurocytomas: a 35-year multi-institutional experience. Journal of Neuro-Oncology, 180(1), Article 19. https://doi.org/10.1007/s11060-026-05825-8

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05825-8

Keywords: central neurocytoma, brain tumor, recurrence, Ki-67, adjuvant radiotherapy, salvage radiotherapy, gross total resection, prognostic markers, neuro-oncology, WHO grade 2, Kaplan-Meier, Cox regression